LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that it has begun a phase III study to evaluate its Iosmapimod drug in patients with acute coronary syndrome.
The study will evaluate whether the drug can reduce the risk of cardiac events such as heart attacks when administered twice a day for three months.
"The start of our losmapimod study is an important step forward in the search for innovative therapies aimed at reducing the recurrence of cardiovascular events," said Senior Vice President of Metabolic Pathways and Cardiovascular R&D John Lepore.
Losmapimod is also being studied as a possible treatment for chronic obstructive pulmonary disease.
Shares in GlaxoSmithKline PLC were trading up 0.1% at 1,582.50 pence Thursday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)